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Abstract
Differentiation of pluripotent cells into differentiated cell types involves changes in many aspects of cellular biochemistry.
Many of these changes result in alterations of gene expression, which may occur by changing the activity of transcription
factors. The cell line NTERA-2 (NT2) can be differentiated into various cell types by incubation with retinoic acid. The
differentiated cell type is also permissive for infection with the human herpesvirus cytomegalovirus (CMV). The transcription
factor YY1 has been shown to regulate the immediate-early promoter of CMV in a differentiation specific manner by binding
to one site at 3958 to 3950 and to at least two sites in the enhancer. It is demonstrated here that there is a second YY1 site in
the modulator between 3995 and 3987. Levels of YY1 DNA binding activity and protein decrease in NT2 cells as they are
differentiated with retinoic acid. This decrease in protein is due to the degradation of YY1 by a cathepsin B-like activity
found in nuclear extracts. The cleavage products of YY1 include the intact C-terminal half of the protein, which contains the
zinc fingers and the DNA binding activity. This suggests a mechanism that allows expression of the CMV immediate-early
promoter in differentiated cells. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Gene expression is often regulated at the level of
transcription initiation via the binding of transcrip-
tion factors to promoters and other transcriptional
regulatory sequences. Therefore the amount and type
of transcription factors found within a cell at any
given time are major factors in controlling di¡eren-
tial gene expression. While the levels of various tran-
scription factors found within a cell ares often at the
level of transcription of the genes encoding the fac-
tors, post-translational mechanisms have also been
shown to be a signi¢cant mechanism of regulation
[1]. One fundamental question in biology is how
gene expression is regulated during di¡erentiation
of pluripotent cells into speci¢c cell types. One way
this may occur is through changes in the activity of
transcription factors during di¡erentiation.
The NTERA-2/cl.D1 (NT2) cell line was derived
from a human teratocarcinoma and has been studied
as a model system for cellular di¡erentiation [2].
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When NT2 cells are treated with 1035^1036 M reti-
noic acid (RA) for 5^7 days they di¡erentiate into
various cell types ([3] ; reviewed in [4]). This di¡er-
entiation is accompanied by a slowing in the growth
rate and eventual establishment of a mortal cell cul-
ture with a limited life span. While the exact type of
cells that result from RA treatment of NT2 cells is
poorly de¢ned, some resemble cells of gut epithelium
and neuronal lineages [5].
Of note is that undi¡erentiated NT2 cells are non-
permissive for infection with human cytomegalovirus
(CMV), a member of the herpesvirus family. How-
ever, NT2 cells that have been di¡erentiated with RA
are fully permissive for infection with CMV, allowing
complete replication of virus and production of in-
fectious viral particles [6,7]. This phenomenon has
been attributed to the expression of the critical major
immediate-early (MIE) gene of CMV in a di¡eren-
tiation speci¢c matter [8^10]. The proteins expressed
from the MIE gene have numerous functions in reg-
ulating viral gene expression and are considered es-
sential for further viral replication [11^13]. The reg-
ulation of the MIE promoter in NT2 cells has been
linked to the presence of a modulator sequence lo-
cated 31100 to 3900 from the start site of transcrip-
tion, which appears to inhibit expression of the MIE
promoter in undi¡erentiated cells, but enhances ex-
pression in di¡erentiated cells [14,15]. The modulator
binds several cellular proteins, some of which appear
to be di¡erentiation speci¢c [15^17]. However, it has
been shown that a mutant version of HCMV that
lacks this modulator region is still unable to infect
undi¡erentiated cells, suggesting that other mecha-
nisms may also play a role in regulating the expres-
sion of the MIE gene [18].
One of the di¡erentiation speci¢c factors that bind
to the modulator is the cellular transcription factor
YY1 [19]. YY1, which was initially identi¢ed as a
transcriptional regulator of the adeno-associated vi-
rus (AAV) P5 promoter [20], is also known as delta,
NF-E1, and UCRBP [21^23]. YY1 contains a zinc
¢nger DNA binding domain and its preferred bind-
ing site is 5P-CGGCATNTT-3P [20], yet it also has a
high degree of £exibility in the actual DNA sequen-
ces it will recognize [24]. Since its discovery, YY1 has
been shown to regulate transcription from a variety
of promoters, both viral and cellular [25,26] in either
a negative or positive fashion, depending on the sys-
tem examined (reviewed in [27]). In some cases, the
ability of YY1 to regulate transcription can be al-
tered by the presence of other proteins [28^30]. Fi-
nally, YY1 acts at initiator sequences [31], can bind
and modulate the activity of other cellular transcrip-
tion factors [27,32], and is localized to the nuclear
matrix within cells [33].
During work to elucidate the role of YY1 in reg-
ulating the expression of the immediate-early gene
from CMV, an increase in degradation of YY1 was
observed in di¡erentiated NT2 cells. This degrada-
tion is likely due to a protease with cathepsin B-
like activity, which was identi¢ed in nuclear extracts
from di¡erentiated cells and shown to cleave YY1 in
vitro. The potential role of this protease to alter the
levels of YY1 and increase gene expression from the
CMV immediate-early promoter in di¡erentiated
cells is discussed.
2. Materials and methods
2.1. Materials
Protease inhibitors, antipain, aprotinin, bestatin,
chymostatin, E-64, EDTA, leupeptin, Pefabloc SC,
pepstatin, phosphoramidon, and PMSF were pur-
chased from Boehringer Mannheim (Indianapolis,
IN). Bovine spleen cathepsin B and all-trans-retinoic
acid were purchased from Sigma (St. Louis, MO).
Anti-YY1 was a gift from Tom Shenk, Princeton
University (Princeton, NJ). The TNT coupled in vi-
tro transcription/translation system was purchased
from Promega (Madison, WI) and the [35S]meth-
ionine and [35S]cysteine were purchased from
Amersham (Piscataway, NJ).
2.2. Cell culture
The cell lines used in this study were HeLa
(ATCC-2), NTERA-2/cl.D1 (NT2, ATCC-1973),
and primary human foreskin ¢broblasts (HF). All
cells were maintained in Dulbecco’s modi¢ed Eagle’s
medium (DMEM) containing 10% fetal bovine se-
rum (FBS). HF cells were used between passages 6
and 20. To maintain NT2 cells in the undi¡erentiated
state, cells were split by rolling sterile glass beads
over the surface of the monolayer until the cells de-
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tached. To di¡erentiate NT2 cells, 106 cells were split
into DMEM/10% FBS containing 1036 M all-trans-
retinoic acid and grown for 5^7 days. These cells
were then split 1:3 into growth medium lacking
RA and maintained for 1^2 weeks.
2.3. Cell extracts
Nuclear and cytoplasmic cell extracts were ob-
tained either using the procedure of Dignam [34]
(dounced extracts) or a modi¢cation of this proce-
dure (Triton X-100 lysis extracts). Brie£y, subcon£u-
ent to con£uent monolayers of cells were washed
twice with cold PBS, scraped into PBS and pelleted
brie£y in a microcentrifuge. Cells were disrupted by
the addition of lysis bu¡er (150 mM NaCl, 1 mM
MgCl2, 1 mM Tris (pH 8.0), 0.08% Triton X-100,
10 Wg/ml leupeptin, 5 mM PMSF), vortexing, and
incubating on ice for 5 min. The mixture was centri-
fuged at 4000 rpm for 5 min at 4‡C, supernatant
removed (cytoplasmic extract), aliquoted, frozen in
liquid N2, and stored at 380‡C. Crude nuclei in
the pellet were resuspended in Dignam C bu¡er
(20 mM HEPES (pH 7.9), 1.5 mM MgCl2, 0.5 mM
DTT, 25% glycerol, 0.2 mM EDTA, 420 mM NaCl,
5 mM PMSF, 10 Wg/ml leupeptin) and incubated on
ice for 30^45 min with occasional mixing. This was
centrifuged for 10 min at 4‡C at 15 000 rpm and the
supernatant was removed (nuclear extract), ali-
quoted, frozen in liquid N2 and stored at 380‡C.
In those extracts used for protease assays, no pro-
tease inhibitors were included in the Dignam C bu¡-
er. Protein concentration was determined using the
Bradford assay (Bio-Rad, Hercules, CA).
2.4. Electrophoretic mobility shift assay (EMSA)
Oligonucleotides containing the binding sites for
various transcription factors were either obtained
from commercial sources or based on sequences
used in previously published research: SP-1 oligonu-
cleotide (Promega), major late transcription factor
site (MLTF) [35], and the YY1 site from the AAV
P5+1 promoter [20]. The oligonucleotides containing
the CMV YY1 sites were as follows, where the YY1
site is underlined: (left site ; 3995 to 3987) 5P-
TATGGCATATTGAAAATGTCGCCGATGTGA-
GT-3P ; (right site; 3958 to 3950) 5P-GTAACTGA-
TATCGCCATTTTTCCAAAAGTTGA-3P. Comple-
mentary single-stranded oligonucleotide primers were
end-labeled with [Q-32P]ATP (Amersham) and poly-
nucleotide kinase (New England BioLabs, Beverly,
MA), according to the manufacturer’s instructions.
Unincorporated nucleotide was removed using a Se-
phadex G-50 spin column. Labeled complementary
primers were allowed to anneal by heating to 70‡C
for 5 min and cooled slowly to room temperature.
Each binding assay consisted of 1Ubinding bu¡er
(12 mM HEPES, pH 7.9, 60 mM KCl, 5 mM MgCl2,
1 mM DTT, 0.5 mM EDTA, 10% glycerol, 50 Wg
bovine serum albumin (BSA), and 0.05% NP-40),
10 000^20 000 cpm of labeled oligonucleotide, 1 Wg
poly(dI-dC) DNA, and 5 Wg of the appropriate nu-
clear extract. Histidine-tagged YY1 puri¢ed from Es-
cherichia coli (400 ng) was added to the positive con-
trol assays. Assays were incubated at room
temperature for 30 min, and then loaded onto a
4% polyacrylamide gel in 0.25UTris-borate running
bu¡er (22 mM Tris, 22 mM boric acid, 0.1 mM
EDTA), which had been pre-electrophoresed for
30 min at 150 V. Electrophoresis continued for 90^
120 min at 150 V. The gel was dried onto DE81
(Whatman) paper and exposed to X-ray ¢lm at
380‡C with an intensifying screen.
2.5. Western blot
Equal amounts of cell extracts were boiled in sam-
ple bu¡er and proteins separated by SDS-PAGE.
Gels were blotted onto 0.45 Wm nitrocellulose (Bio-
Rad) and blocked in TBST (Tris bu¡ered saline,
0.05% Tween 20) containing 10% non-fat dried
milk at room temperature for 1 h. Antibodies were
diluted in TBST containing 1% non-fat dried milk
and incubated with the blot for 1 h at room temper-
ature for the primary antibody (monoclonal anti-
body against YY1; gift of Tom Shenk, Princeton
University) and 20^30 min for secondary antibody
(goat-anti-mouse conjugated to horseradish peroxi-
dase, Bio-Rad). Blots were washed 5 times 5 min in
TBST between all antibody incubations. Blots were
developed with the ECL chemiluminescent detection
reagents according to the manufacturer (Amersham),
and exposed to X-ray ¢lm.
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2.6. In vitro protease assays
Radiolabeled YY1 protein was produced from the
plasmid pON7-YY1 (gift of Tom Shenk, Princeton
University), which contains the YY1 cDNA under
the control of the T7 promoter, using either
[35S]methionine or [35S]cysteine and the TNT in vitro
transcription/translation system (Promega). Quality
and speci¢c activity of the labeled proteins were de-
termined by SDS-PAGE/autoradiography and TCA
precipitation. Each protease assay consisted of 20 000
cpm of 35S-labeled YY1 protein and 10^20 Wg of
nuclear extract in a ¢nal reaction of 30 mM HEPES
(pH 7.9), 3 mM MgCl2, 150 mM NaCl, 0.2 mM
Fig. 1. YY1 can bind to a second site in the modulator of the CMV immediate-early promoter. (A) Diagram depicting some of the
protein binding sites in the CMV immediate-early promoter/enhancer region (31150 to +50). The arrow shows the start site of tran-
scription. (B) Nuclear extracts from undi¡erentiated (3RA) and di¡erentiated NT2 cells (+RA) were incubated with labeled oligonu-
cleotides containing either the left CMV YY1 site (lanes 1^12), the right CMV YY1 site (lanes 13^24), or the AAV P5+1 site (lanes
25^32). Lane 3, no protein; lane +, 400 ng of histidine-tagged YY1 puri¢ed from E. coli. Protein/DNA complexes were separated on
a 4% non-denaturing polyacrylamide gel and visualized by autoradiography. For competition reactions with the CMV probes, either
unlabeled P5+1 or MLTF oligonucleotides were added to the reactions at 10 or 100 times the amount of the labeled oligonucleotide.
For competition reactions with the AAV P5+1 probe, unlabeled HCMV left site (LS) or right site (RS) oligonucleotides were added
at 100 times the amount of labeled oligonucleotide. Band a shows the typical mobility of the YY1/DNA complex.
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DTT, and 0.1 mM EDTA. For reactions containing
puri¢ed cathepsin B, purchased lyophilized enzyme
was dissolved in dH2O at 0.1 unit/Wl, which was
added in place of cell extract, and the balance of
the protein made up with bovine serum albumin.
Protease inhibitors were added to the reactions
from appropriate stock solutions before addition of
the substrate protein. Reactions were incubated at
30‡C for 15 min, then an aliquot of 4Uprotein sam-
ple bu¡er (8% SDS, 0.2 M Tris pH 6.8, 0.1% bro-
mophenol blue, 20% L-mercaptoethanol) was added
and tubes incubated at 94‡C for 5 min. Proteins were
separated by 12% SDS-PAGE. Gels were ¢xed in
30% methanol/10% acetic acid for 1 h and incubated
in 1 M sodium salicylate, 5% glycerol for 30 min,
dried and exposed to X-ray ¢lm with an intensifying
screen.
3. Results
3.1. A second YY1 binding site exists in the CMV
modulator region
Previous work has shown that the cellular tran-
scription factor YY1 is capable of binding to one
site in the modulator region, between 3958 and
3950, and to at least two sites in the enhancer region
of the CMV MIE promoter [19]. Upon inspection of
the modulator region it became apparent that a sec-
ond potential YY1 site exists between bases 3995
and 3987, upstream from the one previously de-
scribed in the modulator (Fig. 1A). To determine if
this site could actually be bound by YY1, extracts
from undi¡erentiated and di¡erentiated NT2 cells
were tested in EMSA on both the left (3995 to
3987) and right (3958 to 3950) CMV sites, as
Fig. 2. Levels of YY1 DNA binding activity are decreased in nuclear extracts from di¡erentiated NT2 cells. Nuclear extracts from un-
di¡erentiated NT2 cells (UT), retinoic acid di¡erentiated NT2 cells (DT) or HeLa cells (HL) were assayed for various DNA binding
activities with EMSA. Ten micrograms of protein were incubated with 32P-labeled DNA oligonucleotides containing SP1, MLTF, or
YY1 binding sites (CMV-LS, CMV-RS, AAV-YY1) and protein/DNA complexes were separated on a 4% non-denaturing polyacryl-
amide gel and visualized by autoradiography. Band a shows the typical mobility of the YY1/DNA complex and band b shows the
faster migrating complex.
BBADIS 62023 24-4-01
M.C. Pizzorno / Biochimica et Biophysica Acta 1536 (2001) 31^42 35
well as with the known YY1 binding site (AAV P5+1
[20]) (Fig. 1B). It is clear that YY1 is capable of
recognizing all three DNA sequences, since incuba-
tion of each probe with YY1 produced in E. coli
gives rise to a shifted band (Fig. 1B, band a in lanes
2, 14, and 26). Furthermore, a protein in undi¡eren-
tiated NT2 extracts is capable of recognizing all three
YY1 sites and gives a shifted complex similar in mo-
bility to that of the recombinant YY1 (Fig. 1B, lanes
3, 15 and 27). Since unlabeled P5+1 oligo, but not
MLTF oligo, can compete o¡ protein bound to both
CMV sites, the protein bound to the DNA is most
likely YY1 (Fig. 1B, lanes 4^7, 16^19). This is also
supported by the observation that both of the CMV
sites can compete o¡ a protein bound to the AAV
P5+1 site (Fig. 1B, lanes 28^29). It is interesting to
note that there is very little YY1 DNA binding ac-
tivity in the extracts from di¡erentiated NT2 cells
and a faster migrating band is seen in both NT2
extracts (Fig. 1B, band b in lanes 8^12, 20^24 and
30^32). This band is also competed with either the
P5+1 oligo or the CMV oligos, but not the MLTF
oligo, suggesting the bound protein is recognizing the
same sequence as YY1 and may be a smaller but
related protein bound to the same site.
3.2. Di¡erentiation of human teratocarcinoma cells
leads to a reduction in the amount of YY1 DNA
binding activity
To further elucidate the levels of YY1 DNA bind-
ing activity in NT2 cells, nuclear extracts from un-
di¡erentiated and di¡erentiated NT2 cells were com-
pared with nuclear extracts from HeLa cells for the
levels of several transcription factors. These mobility
shift experiments demonstrate that in nuclear ex-
tracts from di¡erentiated NT2 cells there was signi¢-
cantly less of the shifted YY1/DNA complex on ei-
ther of the CMV sites or the P5+1 site (Fig. 2, lanes
11, 15, and 19). Scintillation counting of the shifted
complexes showed that the level of the YY1/DNA
complex in the di¡erentiated cell extracts is 10-fold
lower than that of the undi¡erentiated NT2 or HeLa
cells (data not shown). In addition, there was a slight
increase in the faster migrating protein/DNA com-
plex, suggesting the presence of a smaller protein
bound to the oligonucleotide in extracts from the
di¡erentiated cells. HeLa cells, however, demonstrate
greater levels of the YY1/DNA complex and very
little to none of the faster running complex. Since
the P5+1 oligonucleotide can compete o¡ this faster
migrating complex (Fig. 1B), it is likely that it rep-
resents a smaller YY1/DNA complex.
The sequence of the YY1 site tested does not ap-
pear to alter the ratio of the larger complex to the
smaller complex as the e¡ect was noted with all three
YY1 binding sites tested (Fig. 2). It should also be
noted that other cellular transcription factors, such
as SP1 and MLTF, have similar DNA binding activ-
ities in extracts prepared from all three cell lines (Fig.
2, lanes 1^8). This demonstrates that the lack of YY1
activity in the di¡erentiated cells is not likely the
result of a general repression of gene expression or
a non-speci¢c protease capable of degrading all of
the transcription factors present in the extract.
Western blot analysis of the nuclear extracts from
NT2 cells, both undi¡erentiated and di¡erentiated
with retinoic acid for various lengths of time, was
Fig. 3. Levels of full-length YY1 protein decrease as NT2 cells
are di¡erentiated in retinoic acid. NT2 cells incubated for vari-
ous times in 1036 M all-trans-retinoic acid were harvested and
nuclear extracts prepared. Equal amounts of nuclear extracts
were separated on a 10% SDS-polyacrylamide gel, blotted to ni-
trocellulose, and probed with a YY1 speci¢c monoclonal anti-
body.
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performed to determine the levels of YY1 protein. It
was observed that the overall level of the full-length
YY1 declined as the NT2 cells were incubated for
longer times in retinoic acid and developed into a
more di¡erentiated cell type (Fig. 3). At the same
time, the level of a smaller YY1 fragment became
more prominent during this time period. The levels
of the smaller form of YY1 increase as the cells are
incubated in 1036 M retinoic acid for 1^9 days,
though it appears to peak between days 5 and 7.
During this time the cells become terminally di¡er-
entiated as noted by changes in their cellular mor-
phology and eventual assumption of a mortal cell
phenotype. The primary breakdown product that
was recognized by the monoclonal antibody was ap-
prox. 30 kDa in size.
3.3. Di¡erentiated cells contain a protease capable of
degrading YY1 in vitro
An in vitro assay was developed to study the po-
tential protease activity identi¢ed in di¡erentiated
cells. In the assay, [35S]methionine-labeled YY1 was
synthesized in vitro and incubated with various cel-
lular extracts. The cleavage products were then ana-
lyzed by SDS-PAGE and autoradiography. The in
vitro protease assay was carried out with equal
amounts of nuclear extract from several cell types
that are of di¡erent levels of cellular di¡erentiation,
including the highly transformed cancer cell line,
HeLa, and fully di¡erentiated normal human ¢bro-
blast, HF. Some degradation of the intact YY1 pro-
tein (68 kDa) was observed in each of the extracts
tested; however, the greatest level of cleavage was
observed in extracts from more highly di¡erentiated
cell types (Fig. 4, lanes 2, 4^6).
By far the highest level of YY1 degradation was
observed in the nuclear extracts from human diploid
¢broblasts. Equal amounts of nuclear extracts from
three separate HF isolates (Fig. 4, lanes HF1, HF2
and HF3) showed nearly complete degradation of
the substrate protein into two major cleavage prod-
ucts of approx. 30 and 35 kDa. In vitro transcribed/
translated YY1 incubated without nuclear extract
does not show these two major cleavage products
(Fig. 4, lane 7). The cell line that has the next highest
level of protease activity is NT2 di¡erentiated with
retinoic acid. This is compared with extracts from
two undi¡erentiated cell lines, untreated NT2 cells
and HeLa cells, which show very low levels of pro-
tease activity (Fig. 4, lanes 1 and 3). Further experi-
ments suggest that there are moderate levels of pro-
tease activity in the semi-di¡erentiated cell line U373-
MG (data not shown).
Fig. 4. In vitro protease assay shows high levels of YY1 degradation in nuclear extracts from di¡erentiated cell types. Twenty micro-
grams of nuclear extract from each of the cell types tested were incubated with 20 000 cpm of 35S-labeled YY1 protein at 30‡C for
20 min, the products separated by 10% SDS-PAGE and visualized by autoradiography.
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3.4. Protease activity appears to have activity related
to cysteine protease cathepsin B
To identify what class of protease was cleaving
YY1 a series of protease inhibitors were tested in
the in vitro protease assay. Labeled YY1 substrate
protein was incubated with bu¡er alone, 20 Wg of
nuclear extract from HF cells, or HF nuclear extract
containing one of several protease inhibitors. Sub-
strate protein alone (Fig. 5, lanes 12 and 13) shows
little degradation in the absence of nuclear extract,
yet the two prominent cleavage products of 30 and
35 kDa are visible when the protein is incubated with
nuclear extract from HF cells (lane 1). Four of the
inhibitors were able to completely prevent the cleav-
age of the substrate when used in normal working
concentrations, antipain, chymostatin, E-64, and leu-
peptin (Fig. 5, lanes 2, 5, 6, and 8). Sensitivity to
these four inhibitors suggests that the protease is a
member of the cysteine protease family (reviewed in
[36]).
Since a common cysteine protease found in cells is
the lysosomal protease cathepsin B, an experiment
was performed to determine if the protease activity
observed could be cathepsin B or a protease with
related activity. To determine this, a protease assay
was conducted comparing puri¢ed cathepsin B from
bovine spleen with the protease activity observed in
HF nuclear extracts. Substrate protein was incubated
with increasing amounts of either HF nuclear extract
or puri¢ed cathepsin B. At the highest level of nu-
clear extract and the lowest level of cathepsin B, the
cleavage pro¢les appear nearly identical (Fig. 6, lanes
5 and 6). While a few minor di¡erences exist between
the fragments produced by the nuclear extract and
the puri¢ed enzyme, most notably an extra fragment
of approx. 40 kDa in the cathepsin B samples, the
majority of the bands produced are of a similar size.
Higher levels of puri¢ed cathepsin B lead to further
cleavage of the substrate producing increasingly
smaller fragments that are not observed with the nu-
clear extract.
Fig. 5. Inhibitors speci¢c for cysteine proteases a¡ect YY1 degrading activity. In vitro protease assay containing 20 Wg of HF nuclear
extract and 20 000 cpm of 35S-labeled YY1 without any inhibitor (lane 1) or with 50 Wg/ml antipain (lane 2), 2 Wg/ml aprotinin (lane
3), 40 Wg/ml bestatin (lane 4), 100 Wg/ml chymostatin (lane 5), 10 Wg/ml E-64 (lane 6), 0.5 mg/ml EDTA (lane 7), 0.5 Wg/ml leupeptin
(lane 8), 0.5 mg/ml Pefabloc SC (lane 9), 0.7 Wg/ml pepstatin (lane 10), or 0.33 mg/ml of phosphoramidon (lane 11), no extract (lane
12) and bu¡er control (lane 13). Cleavage products were separated by 10% SDS-PAGE and visualized by autoradiography. Band a
shows mobility of full-length YY1 protein and bands b and c show position of the cleavage products.
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While similarly sized cleavage products do not
con¢rm that the activity is identical, taken together
with the inhibitor data this suggests that this
protease activity is cathepsin B or a related activ-
ity.
3.5. Cleavage of YY1 by nuclear cathepsin B-like
protease leaves intact carboxy-terminal domain
In the predicted amino acid sequence of YY1 [20]
there are no cysteines in the amino-terminal half of
Fig. 6. The cleavage pattern produced by HF nuclear extract is similar to that produced by puri¢ed cathepsin B. In vitro protease as-
say with either increasing levels of puri¢ed bovine spleen cathepsin B or HF nuclear extract and equal amounts of [35S]methionine-la-
beled YY1. Cleavage products were separated by 10% SDS-PAGE and visualized by autoradiography. Lane 1 contains 10 Wg of bo-
vine serum albumin (BSA); lanes 2^5 contain from 0.01 Wg to 10 Wg of HF nuclear extract; lanes 6^11 contain 10 Wg of BSA and
from 0.005 to 0.5 units of puri¢ed bovine spleen cathepsin B.
Fig. 7. The larger cleavage products of YY1 represent the carboxyl-terminal portion of the protein. Labeled substrate YY1 was pro-
duced by in vitro transcription/translation with either [35S]cysteine (lanes marked C) or [35S]methionine (lanes marked M) and incu-
bated at 30‡C for 20 min with 20 Wg of nuclear extract from either undi¡erentiated NT2 cells (3RA) or di¡erentiated NT2 cells
(+RA) produced using either the standard procedure [34] or the modi¢ed Triton X-100 lysis procedure described in Section 2. Cleav-
age products were separated by 10% SDS-PAGE and visualized by autoradiography.
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the protein. Because of this unequal distribution of
cysteines versus methionines, it was possible to com-
pare the cleavage products when the YY1 substrate
protein was labeled separately with each amino acid.
In vitro translated YY1 protein labeled with either
[35S]cysteine or [35S]methionine was compared in the
in vitro protease assay (Fig. 7). It can be seen that
only the 30 kDa cleavage product is visible when
[35S]cysteine-labeled YY1 is incubated with nuclear
extracts from di¡erentiated NT2 while both the 30
kDa and the 35 kDa are visible in the
[35S]methionine-labeled protein, suggesting that the
intact 30 kDa fragment is the carboxyl-terminal seg-
ment of the protein. Since the carboxyl terminal part
of YY1 contains both the zinc ¢nger domain and the
DNA binding activity, it is likely that this protein
fragment is still capable of binding to DNA and
might be giving rise to the faster DNA/protein com-
plex seen in the EMSA (Fig. 1B).
Another observation is that extracts produced by
either the Triton X-100 lysis method or the dounce
homogenization method have similar levels of pro-
tease activity, suggesting that the method used to
produce the nuclear extracts does not change the
amount of activity obtained.
4. Discussion
The full-length MIE promoter/enhancer of CMV
is more highly expressed in di¡erentiated cells than in
undi¡erentiated ones, which has been attributed to a
region of the promoter (31100 to 3900), termed the
modulator [8,9,14,15]. The cellular transcription fac-
tor YY1 is known to bind to several sites within the
immediate-early promoter of cytomegalovirus and
one of these sites is in the modulator region, specif-
ically in the 5P half of a dyad symmetry [16,19]. In
addition, there are at least two YY1 sites in the en-
hancer as part of the 21 bp repeats [19,37]. The data
presented here demonstrate that there is a second
YY1 binding site 28 bases upstream from the 5P
dyad symmetry site and facing in the opposite direc-
tion (Figs. 1 and 2). While the role of this YY1 site
in the regulation of the CMV promoter requires fur-
ther study, it could, along with other factor binding
sites, be involved in the repression of the MIE pro-
moter seen in undi¡erentiated cell types [10,19,38,39].
Di¡erentiation of NT2/D1 cells with retinoic acid
leads to a cell type that is permissive for infection
with CMV [6,7]. It is shown here and by others that
this also leads to a decrease in the levels of YY1
DNA binding activity and YY1 protein [19]. It is
likely that the decrease in YY1 activity in di¡erenti-
ated NT2 cells relieves the repression that YY1 has
on the transcription of the CMV immediate-early
promoter allowing for expression of the MIE pro-
moter and replication of the virus. This decrease in
YY1 is due to proteolytic degradation that can be
replicated in vitro by incubating radiolabeled YY1
protein with nuclear extracts from various cell types.
The level of YY1 speci¢c protease activity varied
among the cell types tested, but in general it ap-
peared highest in human ¢broblasts, which are fully
permissive for infection with CMV, and lower in
HeLa cells and undi¡erentiated NT2 cells, both of
which are non-permissive for infection with CMV.
This proteolytic activity appears to be related to
cathepsin B based both on protease inhibitor sensi-
tivity and the size of digestion fragments of YY1
when compared to those produced by puri¢ed bovine
cathepsin B. The identity of this nuclear cathepsin B-
like protease is as yet unknown, but there are two
possible explanations. One is that this enzyme is a
variant protein synthesized from the normal cathep-
sin B gene [40]. While most of the cathepsin B activ-
ity and protein is localized to the lysosome, there
have been observations of alternative splicing of the
cathepsin B mRNA to produce forms of the enzyme
which do not localize to the lysosome [41]. In addi-
tion, cathepsin B activity has been localized to both
puri¢ed nuclei in cell fractionation experiments [42]
and at the nuclear envelope microscopically [43].
This suggests that some cell types normally have ca-
thepsin B-like activity associated either in the nucleus
or on the nuclear membrane. One caveat of these
observations is that the level of nuclear cathepsin B
activity appeared to be higher in more transformed
cells, which is opposite to the observations made in
the experiments presented here. This suggests that
the YY1 degrading activity observed here might
not be identical to the cathepsin B found in most
cells.
Another possibility is that the protease described
here represents a completely separate enzyme from
cathepsin B. For example, this could be the same
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activity as SPase, a nuclear protease capable of de-
grading the transcription factor SP1 in CV1 cells [44^
46]. SPase appears to have cathepsin B activity but is
immunologically related to cathepsin L, and its ac-
tivity is regulated in a cell cycle dependent manner
[46]. Since SP1 DNA binding activity was not de-
creased in di¡erentiated NT2 cells as compared to
HeLa or undi¡erentiated T2 cells (Fig. 2), it seems
unlikely that the protease observed here is SPase.
Another candidate is the nuclear cathepsin B-like
activity observed in human ¢broblasts that is capable
of degrading the transcription factor AP1 [47]. Since
the levels of AP1 protein or DNA binding activity
were not tested, it is unclear if this could be the same
protease or not. However, others have noted no
change in the levels of AP1 in di¡erentiated NT2
cells [38], which suggests that the YY1 degrading
activity described in this report is entirely novel
and has not been observed previously.
The regulation of YY1 during di¡erentiation is
unclear. Some reports show a change in levels of
YY1 protein during cellular di¡erentiation [48,49],
while in other systems, such as murine F9 cells
treated with retinoic acid and cAMP, there was no
obvious change in YY1 protein levels [50]. The data
reported here are in contrast to the situation with F9
cells, which suggests that the murine F9 and the hu-
man NT2 cells are not identical in their response to
retinoic acid or in their pathways of di¡erentiation.
In addition, Lee and Swartz demonstrate that YY1 is
prone to proteolytic cleavage [51] and they suggest
that in vivo degradation of YY1 may explain the loss
of YY1 protein during terminal di¡erentiation of
primary myoblasts [49,52]. While the level of YY1
present in each of the cell lines used here was not
tested, other reports suggest that it may not correlate
with the levels of proteolytic activity [19]. This may
be due to other factors, such as phosphorylation or
association with other proteins, that regulate the sus-
ceptibility of YY1 to proteolysis. For example, asso-
ciation with the YY1 binding protein YAF2 has been
shown to regulate degradation of YY1 by the calci-
um activated protease m-calpain in di¡erentiating
myoblasts [52]. The data shown here support the
hypothesis that degradation of YY1 may be a crucial
event during di¡erentiation of some cell types and
that di¡erent regulatory mechanisms and proteases
could be involved in each case.
Parallel to the decrease in the YY1/DNA complex
in nuclear extracts from di¡erentiated NT2 cells was
an increase in a faster migrating protein/DNA com-
plex which is competed by a known YY1 binding site
(Figs. 1B and 2). This suggests that cleavage of YY1
by the cathepsin B-like protease creates a proteolytic
fragment of YY1 still capable of binding to DNA.
Also one of the main proteolytic fragments of YY1 is
the C-terminal half (Fig. 7), which contains the zinc
¢ngers and the DNA binding domain and could give
rise to the faster DNA/protein complex seen in
EMSA (Figs. 1B and 2). It has been shown that
the repressor domain of YY1 is also located in the
C-terminal half of the protein [50], while the N-ter-
minal half of the protein appears to have the tran-
scriptional activation domain and protein interaction
domains [49]. This does not directly explain how
cleavage of YY1 could inactivate its ability to repress
transcription; however, it is possible that cleavage
could lead to incorrect folding of the polypeptide
making it unable to interact and compete with other
transcription factors, which could preserve the DNA
binding activity but alter YY1’s ability to repress
transcription. Furthermore, while the proteolytic
fragment appears to have DNA binding activity in
vitro, this fragment may be more susceptible to in
vivo protein degradation by other proteolytic activ-
ities and may not be in high enough concentration to
cause repression of the CMV immediate-early pro-
moter.
Finally, regulation of YY1 degradation needs to
be studied further, including determining whether
the degradation is regulated by the phosphorylation
state of YY1 [50], or if the protease activity is cell
cycle regulated like SPase [46]. If this turns out to be
the case then the steady-state levels of YY1 in a non-
synchronized population of cells may appear con-
stant, which may have complicated the interpretation
of previous experiments designed to study the levels
of YY1 in di¡erentiating cell populations.
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